Glecaprevir/Pibrentasvir for Post Traumatic Stress Disorder
Psychopharmacology Bulletin · 2026
DOI: 10.64719/pb.15419 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Psychopharmacology Bulletin, 2026. Verfasst von Bradley V Watts und 7 weiteren Autor:innen. Beteiligte Einrichtung: Watts, MD, MPH, Larner College of Medicine at the University of Vermont, Burlington VT; White River Junction VA Medical Center, White River Junction …. Hauptthemen laut MEDLINE: Benzimidazoles, Stress Disorders, Post-Traumatic, Quinoxalines, Sulfonamides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
Posttraumatic Stress Disorder (PTSD) is a common condition with few effective medication treatments. Glecaprevir/Pibrentasvir (GLE/PIB), a treatment for hepatitis C virus (HCV) infection, demonstrated possible evidence of effectiveness for PTSD in an epidemiological study. We sought to determine if GLE/PIB decreases the symptoms of PTSD and modulates inflammation.
Methods
An uncontrolled open trial was conducted at the Veterans Affairs Medical Center in White River Junction Vermont. Participants were veterans with PTSD and no HCV infection. Ten participants received Glecaprevir 100 mg/Pibrentasvir 40 mg, three tablets daily for 8 weeks. Symptoms were measured at baseline, mid-treatment, post-treatment, as well as at three- and six-months post-treatment. The primary outcome was PTSD symptoms as measured by the Clinician Administered PTSD Scale for DSM 5 (CAPS-5). Exploratory analyses were conducted to assess serum inflammatory biomarkers at baseline and posttreatment.
Results
The mean baseline CAPS-5 score was 33.6 (SD = 3.3). Six-month post-treatment effects were large (CAPS-5: d = 1.6, p < 0.01). By the end of the study, eight patients met the criteria for response, including eight who met the criteria for loss of PTSD diagnosis and six who met the criteria for total remission of PTSD (CAPS-5 score of less than 12). Lower interleukin (IL)-27 levels prior to treatment were predictive of treatment response. Eight-week IL-9 levels changes with treatment were associated with symptom improvement.
Conclusions
GLE/PIB may be an effective treatment for PTSD. Furthermore, treatment may modulate inflammatory responses in PTSD. Future studies are required to confirm these findings regarding GLE/PIB, PTSD, and inflammation. Psychopharmacology Bulletin. 2026;56(1):28–38.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Watts, MD, MPH, Larner College of Medicine at the University of Vermont, Burlington VT; White River Junction VA Medical Center, White River Junction VT; VA Office of Rural Health, White River Junction VT.
- Hoyt, MPH, White River Junction VA Medical Center, White River Junction VT.
- Disano, PhD, White River Junction VA Medical Center, White River Junction VT; Geisel Medical School at Dartmouth College, Hanover NH.
- Noller, PhD, White River Junction VA Medical Center, White River Junction VT; Geisel Medical School at Dartmouth College, Hanover NH.
- Rozema, MA, White River Junction VA Medical Center, White River Junction VT.
- Foster, MA, White River Junction VA Medical Center, White River Junction VT.
Zitieren
APA
Watts, B. V., Hoyt, J. E., Disano, K. D., Noller, C. M., Rozema, L., Foster, D. M., Vincenti, M., & Shiner, B. (2026). Glecaprevir/Pibrentasvir for Post Traumatic Stress Disorder. Psychopharmacology Bulletin. https://doi.org/10.64719/pb.15419
Vancouver
Watts BV, Hoyt JE, Disano KD, Noller CM, Rozema L, Foster DM, et al. Glecaprevir/Pibrentasvir for Post Traumatic Stress Disorder. Psychopharmacology Bulletin. 2026. doi:10.64719/pb.15419
BibTeX
@article{Watts2026,
author = {Watts, Bradley V and Hoyt, Jessica E and Disano, Krista D and Noller, Crystal M and Rozema, Luke and Foster, Danielle M and Vincenti, Matthew and Shiner, Brian},
title = {Glecaprevir/Pibrentasvir for Post Traumatic Stress Disorder},
journal = {Psychopharmacology Bulletin},
year = {2026},
doi = {10.64719/pb.15419}
}
EUVIMED